EUROPEAN UROLOGY欧洲泌尿外科
EUROPEAN UROLOGY(英文缩写 EUR UROL),ISSN 0302-2838,eISSN 1873-7560,中文译名:欧洲泌尿外科 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 24.344 | Q1 |
| 2022 | 23.400 | Q1 |
| 2023 | 25.300 | Q1 |
| 2024 | 25.200 | Q1 |
| 2025 | 29.100 | Q1 |
EUROPEAN UROLOGY 最新收录文献
-
1. {"_":"Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of Copper [Cu]SAR-bisPSMA vs Gallium [Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol 2026;89:512-20.","sup":["64","64","68","68"]}
1. {"_":"回复：Sobia Khan、Nathan Papa、Andrew Kneebone等。铜[Cu]SAR-bisPSMA与镓[Ga]PSMA-11 PET/CT在根治性前列腺切除术后前列腺癌生化复发中的前瞻性比较（Co-PSMA试验）。Eur Urol 2026;89:512-20。","sup":["64","64","68","68"]}PMID:日期:2026-10-03该文献暂无摘要。
-
2. Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters.
2. 不断积累的证据支持NECTIN4作为恩诺单抗维多汀的预测性生物标志物：区室仍然重要PMID:日期:2026-10-03Accumulating data support nectin-4, particularly membranous expression, as a predictive biomarker of enfortumab vedotin activity. Low expression identifies patients with poorer outcomes but not absence of benefit, underscoring the need for standardized prospective validation before clinical implementation.
-
3. Reply to Paolo Zaurito's Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.
3. 回复Paolo Zaurito致编辑的信，关于Robert M. Meier、Nima Aghdam、Alan C. Beckman等人的文章：前列腺癌立体定向体部放疗的10年生存和毒性结局：一项非随机临床试验。Eur Urol。出版中。http://dx.doi.org/PMID:日期:2026-10-03该文献暂无摘要。
-
4. Reply to Riccardo Lombardo's Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020.
4. 回复Riccardo Lombardo致编辑的信，关于：Bi-Ming He、Keqin Zhang、Zhien Zhou等人。认知融合与基于软件融合的靶向穿刺活检对临床显著性前列腺癌诊断的比较：一项多中心、随机、非劣效性试验（IMAGINATION）。Eur Urol。印刷中。http://dx.doi.org/PMID:日期:2026-10-03该文献暂无摘要。
-
5. PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.
5. 前列腺特异性膜抗原PET/CT引导下的前列腺癌放疗强化（PSMAgRT）：一项2期随机对照试验的5年分析PMID:日期:2026-10-03Prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves lesion detection, leading to treatment intensification via PSMA-guided radiotherapy (PSMAgRT), but its impact on patient outcomes remains undefined. We evaluated whether PSMAgRT improves failure-free survival (FFS). This phase 2, two-center, open-label randomized trial enrolled patients planned for standard-of-care (SOC) radiotherapy (RT). Patients were randomized 1:1 to SOC or PSMAgRT to all detected sites across four strata: salvage post-radical prostatectomy (RP), high-risk, oligometastatic, and salvage post-RT. Between 2018 and 2021, 262 patients were randomized (253 treated/analyzed). The primary FFS end point (measured from RT completion) comprised prostate-specific antigen (PSA)/radiological progression, next-line therapy, or death. Secondary end points included freedom from biochemical progression (FFBP; PSA rise ≥0.2 ng/ml post-RP or ≥2 ng/ml above nadir in other strata). Prespecified analyses used a one-sided threshold of p < 0.10, whereas post hoc analyses used two-sided p < 0.05 thresholds and 95% confidence intervals (CIs). Among 253 patients, median follow-up was 66 mo (range 9-91). The 5-yr primary FFS was 66% with PSMAgRT versus 62% in controls (hazard ratio [HR] = 0.80; one-sided 90% CI, upper bound 1.04; p = 0.14). FFBP favored PSMAgRT: 72% versus 65% overall (subdistribution HR [sHR] 0.70, one-sided 90% CI upper bound 0.92; p = 0.048), 81% versus 66% in patients with high-risk disease (sHR 0.54; p = 0.07), and 80% versus 68% in patients in post-RP stratum (sHR 0.54; p = 0.037). In an exploratory, post hoc analysis combining patients with high-risk disease and those in the post-RP stratum, FFBP favored PSMAgRT (sHR 0.54, 95% CI = 0.32-0.91; two-sided p = 0.02). Only one grade ≥3 event was possibly related to dose escalation. Limitations include a phase 2 design with a heterogeneous population. Although the primary FFS end point was not met in the overall population, treatment-effect estimates favored PSMAgRT in the high-risk and post-RP strata. These findings provide a meaningful rationale for the target populations currently being evaluated in the definitive phase 3 PATRON trial. ClinicalTrials.gov NCT03525288.
-
6. Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer.
6. 回复：高危局限性前列腺癌的围手术期阿帕他胺治疗PMID:日期:2026-10-03该文献暂无摘要。
-
7. Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.
7. 关于微超声引导与MRI引导前列腺癌诊断活检的比较：OPTIMUM随机临床试验PMID:日期:2026-10-03该文献暂无摘要。
-
8. Re: Pierre-Etienne Gabriel, Alec Zhu, Paolo Gontero, Morgan Rouprêt, Evanguelos Xylinas, John P Sfakianos. BCG-unresponsive NMIBC: An Obsolete Definition in a Multimodal and Evolving Therapeutic Landscape. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.028.
8. 回复：Pierre-Etienne Gabriel，Alec Zhu，Paolo Gontero，Morgan Rouprêt，Evanguelos Xylinas，John P Sfakianos。BCG无应答非肌层浸润性膀胱癌：在多模式且不断演变的治疗格局中一个过时的定义。《欧洲泌尿外科学》。出版中。http://dx.doi.org/PMID:日期:2026-10-01该文献暂无摘要。
-
9. Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
9. 回复：CISTO研究比较根治性膀胱切除术与保留膀胱疗法治疗复发性高级别非肌层浸润性膀胱癌的12个月结果PMID:日期:2026-10-01该文献暂无摘要。
-
10. Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
10. 关于斯德哥尔摩3与前列腺特异性抗原在前列腺癌筛查中的比较：STHLM3试验9年结果显示侵袭性癌症检出率提高且过度诊断减少PMID:日期:2026-10-01该文献暂无摘要。